<DOC>
	<DOCNO>NCT00651118</DOCNO>
	<brief_summary>The purpose study determine two allergy medication ( azelastine fluticasone ) effective placebo either medication alone ( azelastine fluticasone )</brief_summary>
	<brief_title>A Study Evaluate Safety Effectiveness Nasal Spray Treat Seasonal Allergies</brief_title>
	<detailed_description>This Phase III , randomize , double-blind , placebo-controlled , parallel-group study subject moderate-to-severe seasonal allergic rhinitis ( SAR ) . The study begin 7-day , single-blind , placebo lead-in period ( Day -7 Day 1 ) . Subjects instructed take placebo lead-in medication twice daily ( 1 spray per nostril ) , approximately every 12 hour . On Day 1 , subject satisfy symptom severity requirement continue meet study inclusion/exclusion criterion randomize 1:1:1:1 ratio receive 1 spray per nostril twice daily MP29-02 , azelastine hydrochloride , fluticasone propionate , placebo nasal spray . Efficacy assess change baseline subject-reported 12-hour reflective Total Nasal Symptom Score ( TNSS ) . On Days 1 14 , subject rate instantaneous reflective TNSS symptom sneeze , nasal congestion , runny nose , nasal itching ; instantaneous reflective total ocular symptom score ( TOSS ) symptoms itchy eye , watery eye eye redness ; symptom postnasal drip , twice daily ( AM PM ) diary prior dose study medication . Symptoms score 0 3 scale ( 0 = symptom , 1 = mild symptom , 2 = moderate symptom , 3 = severe symptom ) , maximum daily symptom severity score 24 TNSS 18 TOSS . Additional secondary efficacy variable include reflective individual nasal ocular symptom score , well change Baseline Day 14 Rhinoconjunctivitis Quality Life Questionnaire ( RQLQ ) . Subjects â‰¥ 18 year age complete RQLQ Day 1 ( prior dosing ) Day 14 . Subjects return clinic Day 7 interim evaluation . After complete 2-week double-blind treatment period , subject return clinic Day 14 ( time early termination ) end-of-study evaluation . Safety tolerability assessment make Days 7 14 . Tolerability evaluate subject-reported adverse event ( AEs ) , nasal examination , vital sign assessment .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>Male female patient 12 year age old 2 year history moderate severe seasonal allergic rhinitis Must generally good health Must meet minimum symptom requirement , specify protocol Must wiling able provide inform consent participate study procedure Positive skin test prevalent spring allergen Exclusion criterion : On nasal examination , presence nasal mucosal erosion , nasal ulceration nasal septal perforation Nasal disease likely affect deposition medication evaluation , sinus infection , nasal polyp severe deviate septum Nasal sinus surgery within previous 6 month Chronic sinus infection ( 3 per year ) Planned travel outside study area study period Use investigational drug within 30 day first visit Hypersensitivity ( bad reaction ) azelastine hydrchloride nasal spray ( Astelin ) , fluticasone propionate nasal spray ( Flonase ) Women use acceptable method birth control Women pregnant nursing Upper respiratory tract infection common cold , flu , sinus infection within 2 week first study visit Asthma lung disease COPD . Mild asthma symptom may consider consultation investigator Irregular heartbeat symptomatic heart condition History alcohol drug abuse History glaucoma Use medication could affect study result</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>